Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces the appointment of Dr Jamie Platt as Chief Operations Officer. Jamie will be based at Research Triangle Park, NC, and will drive operational excellence across the organization, including both the UK and the US CLIA laboratories.
Jamie brings 15 years of successful clinical diagnostics laboratory leadership experience, having directed the development and validation of numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics. During her tenure at Quest Diagnostics, she drove the early Advanced Sequencing strategy and product portfolio, and further ensured operational success by leveraging industrial-grade high-throughput automation, Six Sigma and Lean.
Jamie received her Ph.D. in Molecular and Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley.
Michael Stocum, Chief Executive Officer of Inivata, said:
“Jamie’s appointment is another step in the expansion of Inivata’s leadership team as we continue to build our commercial and operational capabilities. She has an exceptional background, both in business and science, and I am confident that she will make a significant contribution to our success in bringing the benefits of our InVision™ platform to physicians, patients and partners.”
Dr Jamie Platt, Chief Operations Officer, said:
“It’s an exciting time to be joining Inivata. The Company’s InVision liquid biopsy platform is exceptionally sensitive and I look forward to working with the team as we build on its potential, not just in helping physicians to stratify and better treat patients, but in expanding the use of liquid biopsies in monitoring and future applications.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
Paul Rabin (US)
email@example.com +44 (0)20 3709 5700, +1 516 503 0271
firstname.lastname@example.org +44 (0)7900 430235